Caribou Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $3.49 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.39, a 28.42% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $7.53, a 35.81% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.73, a 15.91% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.12, a 43.75% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $6.65, a 12.61% decline from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $7.61, a 6.14% increase from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $7.17, a 34.82% decline from fiscal 2022.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $11.00, a 360.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.49 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $5.39 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $6.65 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $6.78 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $4.92 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $7.53 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $7.61 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $8.35 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $11.38 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $11.73 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $7.17 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $6.69 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $6.59 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $10.12 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $11.00 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $9.74 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $7.07 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $7.04 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $2.39 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $2.07 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $1.89 10-Q · filed 2021-09-02 | |||
| 2021-03-31 | $2.58 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |